Sacramento News-Online

RNA Interference (RNAi) Therapeutics Landscape to Evolve Substantially With Active Participation of 20+ Key Pharma and Biotech Companies in the Market

 Breaking News
  • No posts were found

RNA Interference (RNAi) Therapeutics Landscape to Evolve Substantially With Active Participation of 20+ Key Pharma and Biotech Companies in the Market

November 24
20:22 2022
RNA Interference (RNAi) Therapeutics Landscape to Evolve Substantially With Active Participation of 20+ Key Pharma and Biotech Companies in the Market
DelveInsight Business Research LLP
Globally, more than 20+ key pharma and biotech companies are actively working on 90+ pipeline drugs in the RNA Interference therapeutics landscape based on different Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

RNA Interference (RNAi) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  RNA Interference Market. 

The RNA Interference Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

RNA Interference Pipeline Analysis

RNA Interference Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into emerging therapies in the RNA Interference Market and the aggregate therapies developed by major pharma companies.

  • It accesses the different RNA Interference therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the RNA Interference Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Delveinsight’s Report Covers Around 90+ Products Under Different Phases of Clinical Development Like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn More About the Ongoing Clinical & Commercial Activities in the RNA Interference Therapeutic Market @

RNA Interference Therapeutics Landscape

There are approx. 20+ key companies developing therapies based on RNA Interference. Currently, Alnylam Pharmaceuticals has its RNA Interference drug candidates in the most advanced stage of clinical development. 

Some of the Companies Developing the RNA Interference Based Therapies in the Market Include:

  • Alnylam Pharmaceuticals

  • Suzhou Ribo Life Science

  • Arrowhead Pharmaceuticals

  • Dicerna Pharmaceuticals

  • Sylentis

  • Vir Biotechnology

  • Arbutus Biopharma

  • Silenseed

  • OliX Pharmaceuticals

  • Bio-Path Holdings

  • Janssen Pharmaceuticals

  • Eli Lilly and Company

  • Amgen

  • Sirnaomics

  • Silence Therapeutics

  • Phio Pharmaceuticals

  • Medesis Pharma

  • Atalanta Therapeutics

  • Mirimus/ Biogen

  • Mallinckrodt/Silence Therapeutics

And many others

RNA Interference Emerging Drugs Covered and Analyzed in the Report Include:

  • Vutrisiran: Alnylam Pharmaceuticals

  • Cemdisiran: Alnylam Pharmaceuticals

  • SR061: Suzhou Ribo Life Science

  • ARO-APOC3: Arrowhead Pharmaceuticals

  • DCR-PHXC: Dicerna Pharmaceuticals

And many more

Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. RNA Interference Current Treatment Patterns

4. RNA Interference – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. RNA Interference Late Stage Products (Phase-III)

7. RNA Interference Mid-Stage Products (Phase-II)

8. RNA Interference Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. RNA Interference Discontinued Products

13. RNA Interference Product Profiles

14. Key Companies in the RNA Interference Market

15. Key Products in the RNA Interference Therapeutics Segment

16. Dormant and Discontinued Products

17. RNA Interference Unmet Needs

18. RNA Interference Future Perspectives

19. RNA Interference Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States